BIOMARKERS FOR SCREENING, PREDICTING, AND MONITORING BENIGN PROSTATE HYPERPLASIA

• US 20080050836A1
• Filed: 07/26/2007
• Published: 02/28/2008
• Est. Priority Date: 05/01/1998
• Status: Abandoned Application

• Current Assignee: Health Discovery Corporation
• Original Assignee: Health Discovery Corporation
• Inventors: GUYON, ISABELLE
• Application Number:
  US11/829,039
• Publication Number:
  US 20080050836A1
• Time in Patent Office: Days
• US Class Current: 436/94
• CPC Class Codes: G01N 2800/342 Prostate diseases, e.g. BPH, prostatitis
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Gene expression data are analyzed using learning machines such as support vector machines (SVM) and ridge regression classifiers to rank genes according to their ability to distinguish between BPH (benign prostatic hyperplasia) and all other conditions. Results are provided showing the correlation of results obtained using data from two independent studies that took place at different times using different microarrays. Genes are ranked according to area-under-the-curve, false discovery rate and fold change.

Claims

1. A set of biomarkers for screening, predicting and monitoring benign prostate hyperplasia (BPH) comprising any combination of any two or more genes selected from Unigene ID numbers Hs.100431 (CXCL13), Hs.79389 (NELL2), Hs.556045 (SH3), Hs.79732 (FBLN1), Hs.1104 (BMP5), Hs.89791 (WNT2), Hs.26468 (X11L), Hs.245188 (TIMP3), Hs.95420 (JM27), and Hs.211933 (COL4A2).

2. The set of biomarkers of claim 1, wherein the two or more genes have a value for area-under-curve (AUC) greater than 0.96 and a fold change (FC) greater than 2.

3. The set of biomarkers of claim 1, wherein the two or more genes are involved in the Wnt pathway.

4. The set of biomarkers of claim 3, wherein the two or more genes are Unigene ID numbers Hs.89791 and Hs.1104.

5. The set of biomarkers of claim 4, further comprising Unigene ID number Hs.78061 (TCF21).

6. The set of biomarkers of claim 1, wherein the two or more genes include genes involved in the TGF pathway.

7. The set of biomarkers of claim 6, wherein the two or more genes include Hs. 100431 (CXCL13) and Hs.1104 (BMP5).

8. The set of biomarkers of claim 7, further comprising one or more of Unigene ID numbers Hs. 50924 (GATA-6), Hs.237356 (CXCL12), Hs.251664 (IGF-2), Hs.2025 (TGF-beta) and Hs.8272 (PTGIS).

9. A method for distinguishing between benign prostate hyperplasia (BPH) and non-BPH in a biological sample comprising screening for overexpression of ten or fewer genes selected from the group of genes listed in Table 42 having a value for area-under-curve (AUC) greater than 0.90, a false discovery rate (FDR) less than 0.01, and a value for fold change (FC) greater than 2.

10. The method of claim 9, comprising detecting mRNA for two or more proteins selected from the group consisting of CXCL13, NELL2, BMP5, WNT2, JN27, COL4A2, FOXF2, Adipsin, FBLN1, and WIF-1.

11. A set of biomarkers for use in diagnosing benign prostate hyperplasia (BPH) comprising detecting mRNA for two or more proteins selected from the group consisting of CXCL13, NELL2, BMP5, WNT2, JN27, COL4A2, FOXF2, Adipsin, FBLN1, and WIF-1.